Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants

Kari Buck, Susan G. Amara

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Reuptake systems for monoamines are the initial sites of action for a wide range of therapeutic antidepressants and drugs of abuse, such as cocaine. To delineate structural domains of the dopamine and norepinephrine transporters that contribute to differential interaction with reuptake inhibitors with antidepressant or reinforcing properties, a series of recombinant transporter chimeras were generated and transiently expressed in HeLa cells. The inhibition constants (K(i) values) for cocaine and a variety of selective transport inhibitors were determined for each chimera. Analyses of functional chimeras delineate a segment spanning transmembrane domains 5-7 of the norepinephrine transporter of primary importance for high affinity binding of tricyclic and nontricyclic antidepressants (e.g., K(i) <20 nM desipramine or nisoxetine). In contrast, all chimeras containing dopamine transporter sequences from this region resemble the dopamine transporter, which demonstrates higher affinity for psychomotor stimulants compared with antidepressants (e.g., K(i) = 391 ± 39 nM cocaine compared with 9365 ± 1260 nM desipramine). A region including transmembrane domains 1-3 of the norepinephrine transporter also contributes to the interaction of desipramine and nisoxetine, whereas the analogous region of the dopamine transporter influences the affinity for piperazine derivatives (e.g., GBR12909 and LR1111) that are selective for the dopamine transporter. These analyses provide a framework for identifying the precise structural determinants of monoamine transporters involved in selective interactions with antidepressant and psychomotor stimulant reuptake inhibitors.

Original languageEnglish (US)
Pages (from-to)1030-1037
Number of pages8
JournalMolecular Pharmacology
Volume48
Issue number6
StatePublished - Dec 1995

Fingerprint

Dopamine Plasma Membrane Transport Proteins
nisoxetine
Antidepressive Agents
Catecholamines
Norepinephrine Plasma Membrane Transport Proteins
Desipramine
Cocaine
Tricyclic Antidepressive Agents
Street Drugs
HeLa Cells

ASJC Scopus subject areas

  • Pharmacology

Cite this

Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants. / Buck, Kari; Amara, Susan G.

In: Molecular Pharmacology, Vol. 48, No. 6, 12.1995, p. 1030-1037.

Research output: Contribution to journalArticle

@article{a049493b3c8c47e8a5dad275d04b1207,
title = "Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants",
abstract = "Reuptake systems for monoamines are the initial sites of action for a wide range of therapeutic antidepressants and drugs of abuse, such as cocaine. To delineate structural domains of the dopamine and norepinephrine transporters that contribute to differential interaction with reuptake inhibitors with antidepressant or reinforcing properties, a series of recombinant transporter chimeras were generated and transiently expressed in HeLa cells. The inhibition constants (K(i) values) for cocaine and a variety of selective transport inhibitors were determined for each chimera. Analyses of functional chimeras delineate a segment spanning transmembrane domains 5-7 of the norepinephrine transporter of primary importance for high affinity binding of tricyclic and nontricyclic antidepressants (e.g., K(i) <20 nM desipramine or nisoxetine). In contrast, all chimeras containing dopamine transporter sequences from this region resemble the dopamine transporter, which demonstrates higher affinity for psychomotor stimulants compared with antidepressants (e.g., K(i) = 391 ± 39 nM cocaine compared with 9365 ± 1260 nM desipramine). A region including transmembrane domains 1-3 of the norepinephrine transporter also contributes to the interaction of desipramine and nisoxetine, whereas the analogous region of the dopamine transporter influences the affinity for piperazine derivatives (e.g., GBR12909 and LR1111) that are selective for the dopamine transporter. These analyses provide a framework for identifying the precise structural determinants of monoamine transporters involved in selective interactions with antidepressant and psychomotor stimulant reuptake inhibitors.",
author = "Kari Buck and Amara, {Susan G.}",
year = "1995",
month = "12",
language = "English (US)",
volume = "48",
pages = "1030--1037",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "6",

}

TY - JOUR

T1 - Structural domains of catecholamine transporter chimeras involved in selective inhibition by antidepressants and psychomotor stimulants

AU - Buck, Kari

AU - Amara, Susan G.

PY - 1995/12

Y1 - 1995/12

N2 - Reuptake systems for monoamines are the initial sites of action for a wide range of therapeutic antidepressants and drugs of abuse, such as cocaine. To delineate structural domains of the dopamine and norepinephrine transporters that contribute to differential interaction with reuptake inhibitors with antidepressant or reinforcing properties, a series of recombinant transporter chimeras were generated and transiently expressed in HeLa cells. The inhibition constants (K(i) values) for cocaine and a variety of selective transport inhibitors were determined for each chimera. Analyses of functional chimeras delineate a segment spanning transmembrane domains 5-7 of the norepinephrine transporter of primary importance for high affinity binding of tricyclic and nontricyclic antidepressants (e.g., K(i) <20 nM desipramine or nisoxetine). In contrast, all chimeras containing dopamine transporter sequences from this region resemble the dopamine transporter, which demonstrates higher affinity for psychomotor stimulants compared with antidepressants (e.g., K(i) = 391 ± 39 nM cocaine compared with 9365 ± 1260 nM desipramine). A region including transmembrane domains 1-3 of the norepinephrine transporter also contributes to the interaction of desipramine and nisoxetine, whereas the analogous region of the dopamine transporter influences the affinity for piperazine derivatives (e.g., GBR12909 and LR1111) that are selective for the dopamine transporter. These analyses provide a framework for identifying the precise structural determinants of monoamine transporters involved in selective interactions with antidepressant and psychomotor stimulant reuptake inhibitors.

AB - Reuptake systems for monoamines are the initial sites of action for a wide range of therapeutic antidepressants and drugs of abuse, such as cocaine. To delineate structural domains of the dopamine and norepinephrine transporters that contribute to differential interaction with reuptake inhibitors with antidepressant or reinforcing properties, a series of recombinant transporter chimeras were generated and transiently expressed in HeLa cells. The inhibition constants (K(i) values) for cocaine and a variety of selective transport inhibitors were determined for each chimera. Analyses of functional chimeras delineate a segment spanning transmembrane domains 5-7 of the norepinephrine transporter of primary importance for high affinity binding of tricyclic and nontricyclic antidepressants (e.g., K(i) <20 nM desipramine or nisoxetine). In contrast, all chimeras containing dopamine transporter sequences from this region resemble the dopamine transporter, which demonstrates higher affinity for psychomotor stimulants compared with antidepressants (e.g., K(i) = 391 ± 39 nM cocaine compared with 9365 ± 1260 nM desipramine). A region including transmembrane domains 1-3 of the norepinephrine transporter also contributes to the interaction of desipramine and nisoxetine, whereas the analogous region of the dopamine transporter influences the affinity for piperazine derivatives (e.g., GBR12909 and LR1111) that are selective for the dopamine transporter. These analyses provide a framework for identifying the precise structural determinants of monoamine transporters involved in selective interactions with antidepressant and psychomotor stimulant reuptake inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0029560345&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029560345&partnerID=8YFLogxK

M3 - Article

C2 - 8848002

AN - SCOPUS:0029560345

VL - 48

SP - 1030

EP - 1037

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 6

ER -